WuXi Biologics

Leading global CRDMO for biologics drug development and manufacturing

Company Overview

WuXi Biologics is a leading global contract research, development, and manufacturing organization (CRDMO) for biologics. The company provides end-to-end solutions from antibody discovery to commercial manufacturing. Listed on the Hong Kong Stock Exchange, WuXi Biologics operates facilities across China, Ireland, Germany, Singapore, and the US, and is a critical node in the global pharmaceutical supply chain. The company has been at the center of geopolitical discussions around biotech supply chain security.

Sectors

CRDMOBiologicsDrug Development

Primary Markets

ChinaGlobal

Why This Company Matters

WuXi Biologics is a leading global CDMO enabling biologics discovery, development, and manufacturing, serving over 600 clients worldwide and operating one of the largest single-use bioreactor capacities.

Key Focus Areas

Biologics CDMOAntibody DiscoveryCell Line DevelopmentGlobal ManufacturingBiosafety

Peer Companies

View all

Doctor Anywhere

Southeast Asia's leading omnichannel healthcare platform

Singapore0 signals

M3 Inc.

Japan's largest digital platform for healthcare professionals

Tokyo, Japan0 signals

Ping An Good Doctor

China's leading online healthcare services platform powered by AI diagnostics

Shanghai, China0 signals

Samsung Biologics

Global biopharmaceutical CDMO leader based in South Korea

Incheon, South Korea0 signals

Signal Timeline

1 total

February 2026

ExpansionCanonicalFeb 8

WuXi Biologics Expands Global CDMO Network with New Facility in Singapore

WuXi Biologics has announced the expansion of its global Contract Development and Manufacturing Organization (CDMO) network with a new state-of-the-art biologics manufacturing facility in Singapore. The facility will serve as a key hub for the company's Southeast Asian and global operations, strengthening its capabilities in antibody and cell therapy manufacturing.